Trial Outcomes & Findings for Phenytoin and Multidose Activated Charcoal (NCT NCT00823264)

NCT ID: NCT00823264

Last Updated: 2014-09-11

Results Overview

We enrolled patients with elevated phenytoin levels into the study with greater than 30 ug/cc. The treatment arm received multiple doses of activated charcoal and the control arm received no activated charcoal. We obtained serum phenytoin levels every 6 hours for 24 hours then once every 24 hours. The time to reach a subtoxic level was determined in each arm by looking at serum phenytoin levels and documenting when it was below 25 ug/cc.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

17 participants

Primary outcome timeframe

Serum phenytoin levels were obtained every 6 hours for 24 hours then once every 24 hours

Results posted on

2014-09-11

Participant Flow

Participant milestones

Participant milestones
Measure
Control
Will not receive activated charcoal. Serum levels will be followed.
Multiple Doses of Activated Charcoal
Will receive 50 grams of activated charcoal every 4 hours by mouth until phenytoin level is \< 25 ug/cc.
Overall Study
STARTED
10
7
Overall Study
COMPLETED
8
7
Overall Study
NOT COMPLETED
2
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Control
Will not receive activated charcoal. Serum levels will be followed.
Multiple Doses of Activated Charcoal
Will receive 50 grams of activated charcoal every 4 hours by mouth until phenytoin level is \< 25 ug/cc.
Overall Study
Protocol Violation
2
0

Baseline Characteristics

Phenytoin and Multidose Activated Charcoal

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Control
n=8 Participants
Will not receive activated charcoal. Serum levels will be followed.
Multiple Doses of Activated Charcoal
n=7 Participants
Will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels are \< 25 ug/cc.
Total
n=15 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
n=5 Participants
7 Participants
n=7 Participants
14 Participants
n=5 Participants
Age, Categorical
>=65 years
1 Participants
n=5 Participants
0 Participants
n=7 Participants
1 Participants
n=5 Participants
Sex: Female, Male
Female
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Male
8 Participants
n=5 Participants
7 Participants
n=7 Participants
15 Participants
n=5 Participants
Region of Enrollment
United States
8 participants
n=5 Participants
7 participants
n=7 Participants
15 participants
n=5 Participants

PRIMARY outcome

Timeframe: Serum phenytoin levels were obtained every 6 hours for 24 hours then once every 24 hours

We enrolled patients with elevated phenytoin levels into the study with greater than 30 ug/cc. The treatment arm received multiple doses of activated charcoal and the control arm received no activated charcoal. We obtained serum phenytoin levels every 6 hours for 24 hours then once every 24 hours. The time to reach a subtoxic level was determined in each arm by looking at serum phenytoin levels and documenting when it was below 25 ug/cc.

Outcome measures

Outcome measures
Measure
Control
n=8 Participants
Will not receive activated charcoal. Serum levels will be followed.
Multiple Doses of Activated Charcoal
n=7 Participants
Patients received 50 grams of activated charcoal by mouth every 6 hours until the phenytoin levels was below 25 ug/cc.
Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels
41.1 hours
Interval 11.6 to 196.0
19.3 hours
Interval 13.0 to 33.0

Adverse Events

Multiple Doses of Charcoal

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Brent Morgan

Emory University

Phone: 404-616-4403

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place